JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer

  • 0Endocrine Surgery Division, Department of General and Digestive Surgery, Organización Sanitaria Integrada (OSI) Bilbao-Basurto, Basurto University Hospital, Bilbao, Spain.
Quantitative Imaging in Medicine and Surgery +

|

April 16, 2025

|

April 16, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Dynamic risk stratification for papillary thyroid cancer (PTC) can be improved. Male gender and specific I-131 uptake parameters on SPECT/CT predict non-excellent responses, aiding treatment decisions.

Area Of Science

  • Nuclear Medicine
  • Oncology
  • Radiology

Background

  • Dynamic risk stratification (DRS) is standard for papillary thyroid cancer (PTC) monitoring.
  • Additional variables can optimize patient monitoring strategies.
  • Quantitative SPECT/CT parameters after I-131 treatment may predict treatment response.

Purpose Of The Study

  • To analyze quantitative SPECT/CT parameters post-I-131 treatment.
  • To identify predictors of a non-excellent response (NER) at 1 year.
  • To assess the predictive capacity of these parameters for PTC monitoring.

Main Methods

  • Retrospective observational study of PTC patients treated with I-131.
  • Monitoring based on DRS at 1 year, comparing excellent response (ER) vs. NER.
  • SPECT/CT imaging to analyze I-131 biokinetics in thyroid remnants.

Main Results

  • 19.30% of patients had NER; males had a higher NER rate (45.45%).
  • Total thyroidectomy with bilateral central lymph node dissection was associated with ER.
  • Higher I-131 absorbed activity and accumulated activity correlated with ER.
  • Independent predictors of NER included male gender, % administered activity at 7 days, and absorbed activity per administered activity.
  • The predictive model achieved an AUC of 0.816.

Conclusions

  • Male gender and specific I-131 uptake parameters (absorbed dose, % absorbed dose at 7 days) should supplement DRS in PTC follow-up.
  • These quantitative SPECT/CT parameters can support future clinical decision-making.
  • Integrating imaging biomarkers enhances personalized PTC management.

Keywords: